NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
Clinical Trials
3 trialsNCT03847649 2025-06-11
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT05000710 2024-12-05
CORAL-Lung
Sheba Medical Center
Phase 2 Active not recruiting